Save The Date! May 31-June 1, 2017, San Francisco, CA
2016 Neurotech Investing & Partnering Sponsors
NIO is the first and only trade group that advocates on behalf of companies involved in neuroscience, brain research institutes, and patient advocacy groups across the spectrum of neurological disease, psychiatric illnesses and nervous system injuries. We are disease agnostic, and inclusive of all technology platforms: drugs, devices, software, cell-based therapeutics and diagnostics.
For over a decade, NeuroInsights has been helping entrepreneurs, executives, investors, and governments understand and profit from the growth of drugs, devices and diagnostics for the brain and nervous system. We achieve this through a broad range of strategic business advisory services, in-depth market and industry investment reports.
K&L Gates represents leading global corporations, growth and middle-market companies, capital markets participants and entrepreneurs in every major industry group as well as public sector entities, educational institutions, philanthropic organizations and individuals. Our practice is a robust full market practice — cutting edge, complex and dynamic, at once regional, national and international in scope.
Founded over 30 years ago, Technology Partners manages a total of approximately $700 million of venture capital. Investments are being made currently from Technology Partners VIII, L.P., a $300 million fund.
The Ontario Brain Institute is a provincially‐funded, not ‐for‐profit research centre seeking to maximize the impact of neuroscience and establish Ontario as a world leader in brain research, commercialization and care. Convergent partnerships are created between researchers, clinicians, industry, patients, and their advocates to foster discovery and deliver innovative products and services that improve the lives of those living with brain disorders.
JAZZ Venture Partners is a purpose-built fund focused on Human Performance, investing in transformative opportunities to enhance health, wellness, learning, training, and physical and mental performance. The convergence of neuroscience and widely available digital platforms such as Virtual Reality, Augmented Reality, and Artificial Intelligence has created a massive opportunity to leverage the untapped potential of the human brain. JAZZ funds early stage companies companies driven by passionate entrepreneurs, creating differentiated technologies with a clear path to market. Comprised of entrepreneurs, JAZZ takes a very hands on approach to help build and scale companies, providing a deep roster of support resources required to succeed in this dynamic, multidisciplinary environment.
NTA is an Australian based, not-for-profit contract research organisation specialising in neuroscience clinical research. Our superb range of services will ensure we deliver project in a cost-effective and timely way.Areas of expertise include stroke and stroke-related conditions, multiple sclerosis, epilepsy, Parkinson’s disease, spinal cord injuries, Huntington’s disease, neurosurgery, pain, neuromuscular disease and migraine.
The Association of University Technology Managers is a nonprofit organization dedicated to bringing research to life by supporting and enhancing the global academic technology transfer profession through education, professional development, partnering and advocacy. AUTM’s more than 3,400 members represent managers of intellectual property from more than 300 universities, research institutions and teaching hospitals around the world, as well as numerous businesses and government organizations.
Formed in 2004, Aptuit has since achieved a market leading position in the supply of drug development solutions on a global scale. Initially focused on extending our service offering, we can now offer an unrivalled suite of drug development solutions covering the entire spectrum from discovery through to commercialization.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 15,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health.
Cirtec Medical is a leading provider of advanced outsourcing solutions for Class III active implants (including neuromodulation) and minimally invasive devices. Cirtec offers the tools, expertise and resources needed to make product technology a clinical and commercial reality. From concept to production, fast-growing start-ups to large OEMs, Cirtec delivers innovative solutions.
Piramal Imaging SA (PISA) is an established leader in the field of molecular imaging with an industry leading portfolio of tracers for Alzheimer’s Disease (“AD”) and oncology. PISA is vertically integrated company with a staff of over 70 FTEs, covering radiopharmaceutical products from preclinical R&D through marketing, supported by an experienced management team with an average of over 20 years of experience. PISA’s lead product, NeuraCeq is a Positron Emission Tomography (“PET”) tracer approved in the U.S., EU and South Korea for the detection of β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD. In clinical studies, NeuraCeq has been shown to detect β-amyloid plaques with 98% sensitivity, 89% specificity and 95% accuracy. Following NeuraCeq, PISA has a portfolio of three compounds in development including 68Ga-Bombesin (Phase I/II) for the detection of primary prostate cancer, FSPG (Phase I) for the detection of new and recurrent malignancies in the brain after surgery / radiation, and Tau (in Phase I) for the detection of abnormal folded Tau in AD and other neurodegenerative diseases.
NeuroRx is a clinical stage, small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific. The company’s lead drug candidate is Cyclurad™, the first oral therapeutic for the treatment of acute suicidal crisis associated with bipolar disorder.
To Exhibit or Sponsor
We have space for exhibitors with a variety of booth sizes as well as conference sponsorship opportunities that will identify your company as a leading player. Please contact info@neuroinsights.com for more information.